Suzhou Suncadia Biopharmaceuticals Co., Ltd.
PharmaSuzhou, Jiangsu, China · Est. 2010
Suzhou Suncadia Biopharmaceuticals is a Chinese biopharmaceutical company focused on developing innovative drugs for oncology and other therapeutic areas.
32
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
32
Indications↗
Distinct diseases across all programs
113
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
32 drugs in development
Phase 38
Phase 221
Phase 14
Preclinical5
By Therapeutic Area
top 3
Oncology
2771%
Musculoskeletal
13%
Immunology
13%
R&D Momentum
80/100
Pipeline Velocity
56/100
Trial Completion Rate
58/100
Pipeline Concentration
56/100
Pipeline Freshness
82/100
Strategic Signals
- ↗Active in Musculoskeletal but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 17, 2026
Recruiting
A Randomized, Controlled, Open-label, Multicenter Phase II Clinical Study of SHR-9839 as Monotherapy or in Combination With Chemotherapy Plus Adebrelimab Versus Chemotherapy Plus Adebrelimab in Patients With Advanced Esophageal Squamous Cell Carcinoma
Sep 12, 2026
Recruiting
An Open, Multicenter Phase Ib / II Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Sep 11, 2026
Recruiting
A Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study of SHR-A1811 in Combination With mFOLFOX6 (-1) and Bevacizumab Versus mFOLFOX6 in Combination With Bevacizumab as First-line Treatment for Advanced Colorectal Cancer.
Sep 10, 2026
Recruiting
A Phase III, Multicenter, Randomized, Open-Label Parallel-Controlled Study of Trastuzumab Rezetecan (SHR-A1811) in Combination With Adebrelimab (SHR-1316) Versus Investigator's Choice of Therapy in Subjects With Primary Triple Negative Breast Cancer Who Have Residual Invasive Disease Following Neoadjuvant Therapy
Sep 9, 2026
Recruiting
A Phase II, Multicenter, Open-Label Clinical Study to Evaluate the Safety, Tolerability and Efficacy of SHR-1826 for Injection in Patients With NSCLC
Sep 9, 2026
Recruiting
A Multicenter, Randomized, Double-blind Phase III Study of Intravesical SHR-1501 Combined With Bacillus Calmette Guerin (BCG) Versus Placebo Combined With BCG In Patients With High-risk BCG-naive Papillary-Only Non-muscle-invasive Bladder Cancer (NMIBC)
Sep 9, 2026
Recruiting
A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer
4 more events
Aug 22, 2026TrialA Randomized, Open-label, Multicenter Phase Ib/III Clinical Trial Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian Cancer
Aug 15, 2026TrialAn Open Label, Randomized, Multicenter, Phase III Study of SHR-A2102 in Combination With Adebrelimab Versus Gemcitabine in Combination With Cisplatin/Carboplatin in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (NEC-UC2)
Aug 13, 2026TrialA Multicenter, Open-label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4298 Injection in Patients With Malignant Solid Tumors
Aug 12, 2026TrialAn Open, Multicenter Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Details
Company Info
Therapeutic Focus
oncologyimmunologyrare diseases
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Immunology(1 drug)
—
—
—
1
—
Immunology(1 drug)
Musculoskeletal(1 drug)
—
—
—
1
—
Musculoskeletal(1 drug)
Oncology(27 drugs)
5
4
17
7
—
Oncology(27 drugs)
Unknown / Other(9 drugs)
—
1
9
—
—
Unknown / Other(9 drugs)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)